啟明醫療-B(02500.HK):CEP裝置TriGUARD3在中國完成首例臨牀應用
格隆匯 1 月 20日丨啟明醫療-B(02500.HK)宣佈,其CEP裝置TriGUARD3已於2021年1月15日在中國完成首例臨牀應用,亦是其於亞洲的首例臨牀應用。公司董事會認為,這是實現"腦保護-球囊-瓣膜"產品佈局的重要里程碑。TriGUARD3是一種CEP裝置,旨在向所有三大主動脈血管(頭肱動脈、左頸動脈及左鎖骨下動脈)提供覆蓋,將TAVR及其他結構性心臟手術過程中的腦損傷風險降至最低。
此外,公司自主研發的核心產品VenusA-Plus經導管人工主動脈瓣膜置換系統-可回收輸送系統("VenusA-Plus")已於2020年12月18日獲得泰國公共衞生部食品藥品管理委員會批准上市。這標誌着VenusA-Plus於同年11月中國獲批上市後,在泰國快速獲批上市。
集團是中國首家在中國設立系統化TAVR培訓課程的公司,以推廣我們的TAVR產品以及提高TAVR認知度並推動中國TAV市場的滲透率,並一直在不同醫院向醫生提供有關心臟瓣膜置換術的培訓。集團最近於中國四川省針對其一款TAVR產品VenusA-Plus在外科手術中的應用推出培訓課程,特別是重點介紹了VenusA-Plus可以回收及重用的特點。
由於集團的主要業務在中國,COVID-19冠狀病毒的爆發及中國政府所採取的相應措施對集團的營運造成持續影響,包括(i)我們的醫療器械的審批程序出現若干延誤;(ii)我們的醫療器械的平均售價下降;及(iii)使用我們的醫療器械進行的手術數目低於預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.